Source: GlobalNewswire

Umoja received $100M in Series C Funding

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

25-100

Co-Founder & CEO

Andrew M. Scharenberg

CEO Approval Rating

90/100

Umoja is a Washington-based biotechnology company that develops and commercializes CAR T-cell therapies for the treatment of cancer.